Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides Personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. The company markets its products through internet, word of mouth, and sales force to patients and physicians. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Kontrakty CFD to złożone instrumenty, które wiążą się z dużym ryzykiem gwałtownej straty środków na skutek zastosowania dźwigni finansowej. 76% inwestorów detalicznych odnotowuje straty w handlu kontraktami CFD z tym dostawcą. Powinieneś rozważyć, czy rozumiesz, jak działają kontrakty CFD i czy możesz sobie pozwolić na podjęcie wysokiego ryzyka utraty pieniędzy. Prosimy o zapoznanie się z naszym Oświadczeniem o ryzyku
Oceny i recenzje
Oceny i recenzje
